Emotion Regulation Therapy - Attention Regulation (AR-ERT) for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obsessive-Compulsive Disorder+7 More
Emotion Regulation Therapy - Attention Regulation (AR-ERT) - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether psychological treatment can help people with repetitive negative thinking who have trouble stopping unwanted thoughts and shifting their attention.

Eligible Conditions
  • Obsessive-Compulsive Disorder
  • Major Depressive Disorder (MDD)
  • Anxiety Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Change from Week 0 (baseline) to post-treatment (week 8)

Week 8
Change from baseline in OCD symptom severity at 8 weeks (as measured by the Yale-Brown Obsessive-Compulsive Scale)
Change from baseline in depression symptom severity (as measured by the Structured Interview Guide for the Hamilton Depression Rating Scale)
Change from baseline in functional impairment (as measured by the Work and Social Adjustment Scale)
Change from baseline in generalized anxiety symptom severity (as measured by the Structured Interview Guide for the Hamilton Anxiety Rating Scale)
Change from baseline in mental rituals at 8 weeks (as measured by the Rumination on Obsessions and Compulsions Scale)
Change from baseline in rumination at 8 weeks (as measured by the Rumination Response Scale)
Change from baseline in transdiagnostic repetitive negative thinking at 8 weeks (as measured by the Perseverative Thinking Questionnaire)
Change from baseline in worry at 8 weeks (as measured by the Penn State Worry Questionnaire)

Trial Safety

Safety Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Trial Design

2 Treatment Groups

Supportive Psychotherapy (SPT)
1 of 2
Emotion Regulation Therapy - Attention Regulation (AR-ERT)
1 of 2
Active Control
Experimental Treatment

98 Total Participants · 2 Treatment Groups

Primary Treatment: Emotion Regulation Therapy - Attention Regulation (AR-ERT) · No Placebo Group · N/A

Emotion Regulation Therapy - Attention Regulation (AR-ERT)
Behavioral
Experimental Group · 1 Intervention: Emotion Regulation Therapy - Attention Regulation (AR-ERT) · Intervention Types: Behavioral
Supportive Psychotherapy (SPT)
Behavioral
ActiveComparator Group · 1 Intervention: Supportive Psychotherapy (SPT) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from week 0 (baseline) to post-treatment (week 8)

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,522 Previous Clinical Trials
1,814,492 Total Patients Enrolled
59 Trials studying Obsessive-Compulsive Disorder
12,869 Patients Enrolled for Obsessive-Compulsive Disorder
Massachusetts General HospitalLead Sponsor
2,673 Previous Clinical Trials
30,828,558 Total Patients Enrolled
26 Trials studying Obsessive-Compulsive Disorder
1,616 Patients Enrolled for Obsessive-Compulsive Disorder
Ryan J Jacoby, Ph.D.Principal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
144 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
144 Patients Enrolled for Obsessive-Compulsive Disorder

Eligibility Criteria

Age 18 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
I can speak English fluently and I am willing to provide informed consent to participate in this study and comply with the study protocol.
The ability to use a device with an internet connection, camera, and microphone (e.g.
People aged 18-60 years old are adults.
Massachusetts is a great place to live
from a mental health professional People with repetitive negative thinking, in the form of mental rituals, worries, and/or depressive ruminations, often seek treatment from a mental health professional.
This text is saying that the RNT levels are significant enough to warrant intervention.
You are comfortable and capable of using a computer and completing reaction-time tasks.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.